| Patient characteristics . | Totals . | . | Missinga . |
|---|---|---|---|
| Gender ratio (M:F) | 45:8 | – | |
| Age (median, range); (years) | 38.5 | (0.1–78) | 1 |
| Medical history | 37 | 16 | |
| Healthy | 31 | (83.8%) | |
| Cardiovascular history | 4 | (10.8%) | |
| Other (end stage renal disease, alcoholic liver disease and undiagnosed HIV) | 2 | (5.4%) | |
| Time from vaccination to symptom onset (median, range);(days) | 15.5 | (2–50) | 1 |
| MRI/CT abnormalities (percentage) | 16/22 | (72.7%) | 31 |
| EEG abnormalities (percentage) | 8/9 | (88.9%) | 44 |
| Lumbar puncture (percentage) | 50/53 | (94.3%) | |
| CSF findings | |||
| WBC > 5/μl | 28/38 | (73.7%) | 15 |
| Protein > 50 mg/dl | 29/38 | (76.3%) | 15 |
| YFV RT-PCR in CSF | 2/9 | (22.2%) | 44 |
| Anti-YFV IgM in CSF | 26/31 | (81.2%) | 22 |
| Meningoencephalitis (as reported) | 38 | (73.1%) | |
| Brighton criteria level 1 | – | – | |
| Brighton criteria level 2 | 25 | (65.8%) | |
| Brighton criteria level 3 | 8 | (21.1%) | |
| Misclassification | 1 | (21.1%) | |
| Insufficient data | 4 | (10.5%) | |
| GBS (as reported) | 7 | (13.7%) | |
| Brighton criteria level 1 | – | – | |
| Brighton criteria level 2 | 6 | (85.7%) | |
| Brighton criteria level 3 | – | – | |
| Misclassification | 1 | (14.3%) | |
| ADEM (as reported) | 6 | (11.8%) | |
| Brighton criteria level 1 | 5 | (83.3%) | |
| Brighton criteria level 2 | 1 | (16.6%) | |
| Brighton criteria level 3 | – | – | |
| Myelitis (as reported)b | 5 | (9.4) | |
| Brighton criteria level 2 | 5 | (100%) | |
| Good outcome (for cases with reported outcomes) (percentage) | 35/51 | (68.6%) | 2 |
| Meningoencephalitis | 29/38 | (76.3%) | 2 |
| ADEM | 2/6 | (33.3%) | |
| GBS | 2/7 | (28.6%) | |
| Myelitisb | 2/5 | (40%) | |
| Age in good outcome group (median, IQR (years)) | 32.5 | (18–55) | |
| Age in poor outcome group (median, IQR (years)) | 53 | (21–59) | |
| Therapy (percentage) | 14/53 | (26.4%) | |
| Patient characteristics . | Totals . | . | Missinga . |
|---|---|---|---|
| Gender ratio (M:F) | 45:8 | – | |
| Age (median, range); (years) | 38.5 | (0.1–78) | 1 |
| Medical history | 37 | 16 | |
| Healthy | 31 | (83.8%) | |
| Cardiovascular history | 4 | (10.8%) | |
| Other (end stage renal disease, alcoholic liver disease and undiagnosed HIV) | 2 | (5.4%) | |
| Time from vaccination to symptom onset (median, range);(days) | 15.5 | (2–50) | 1 |
| MRI/CT abnormalities (percentage) | 16/22 | (72.7%) | 31 |
| EEG abnormalities (percentage) | 8/9 | (88.9%) | 44 |
| Lumbar puncture (percentage) | 50/53 | (94.3%) | |
| CSF findings | |||
| WBC > 5/μl | 28/38 | (73.7%) | 15 |
| Protein > 50 mg/dl | 29/38 | (76.3%) | 15 |
| YFV RT-PCR in CSF | 2/9 | (22.2%) | 44 |
| Anti-YFV IgM in CSF | 26/31 | (81.2%) | 22 |
| Meningoencephalitis (as reported) | 38 | (73.1%) | |
| Brighton criteria level 1 | – | – | |
| Brighton criteria level 2 | 25 | (65.8%) | |
| Brighton criteria level 3 | 8 | (21.1%) | |
| Misclassification | 1 | (21.1%) | |
| Insufficient data | 4 | (10.5%) | |
| GBS (as reported) | 7 | (13.7%) | |
| Brighton criteria level 1 | – | – | |
| Brighton criteria level 2 | 6 | (85.7%) | |
| Brighton criteria level 3 | – | – | |
| Misclassification | 1 | (14.3%) | |
| ADEM (as reported) | 6 | (11.8%) | |
| Brighton criteria level 1 | 5 | (83.3%) | |
| Brighton criteria level 2 | 1 | (16.6%) | |
| Brighton criteria level 3 | – | – | |
| Myelitis (as reported)b | 5 | (9.4) | |
| Brighton criteria level 2 | 5 | (100%) | |
| Good outcome (for cases with reported outcomes) (percentage) | 35/51 | (68.6%) | 2 |
| Meningoencephalitis | 29/38 | (76.3%) | 2 |
| ADEM | 2/6 | (33.3%) | |
| GBS | 2/7 | (28.6%) | |
| Myelitisb | 2/5 | (40%) | |
| Age in good outcome group (median, IQR (years)) | 32.5 | (18–55) | |
| Age in poor outcome group (median, IQR (years)) | 53 | (21–59) | |
| Therapy (percentage) | 14/53 | (26.4%) | |
Summary of most important findings of case reports founded in literature.
aMissing refers to the number of cases where the variable was not reported. M, male; F, female; RT-PCR, reverse transcriptase polymerase chain reaction.
bMyelitis was diagnosed in five cases (9.4%), three of whom had concurrent meningoencephalitis.
| Patient characteristics . | Totals . | . | Missinga . |
|---|---|---|---|
| Gender ratio (M:F) | 45:8 | – | |
| Age (median, range); (years) | 38.5 | (0.1–78) | 1 |
| Medical history | 37 | 16 | |
| Healthy | 31 | (83.8%) | |
| Cardiovascular history | 4 | (10.8%) | |
| Other (end stage renal disease, alcoholic liver disease and undiagnosed HIV) | 2 | (5.4%) | |
| Time from vaccination to symptom onset (median, range);(days) | 15.5 | (2–50) | 1 |
| MRI/CT abnormalities (percentage) | 16/22 | (72.7%) | 31 |
| EEG abnormalities (percentage) | 8/9 | (88.9%) | 44 |
| Lumbar puncture (percentage) | 50/53 | (94.3%) | |
| CSF findings | |||
| WBC > 5/μl | 28/38 | (73.7%) | 15 |
| Protein > 50 mg/dl | 29/38 | (76.3%) | 15 |
| YFV RT-PCR in CSF | 2/9 | (22.2%) | 44 |
| Anti-YFV IgM in CSF | 26/31 | (81.2%) | 22 |
| Meningoencephalitis (as reported) | 38 | (73.1%) | |
| Brighton criteria level 1 | – | – | |
| Brighton criteria level 2 | 25 | (65.8%) | |
| Brighton criteria level 3 | 8 | (21.1%) | |
| Misclassification | 1 | (21.1%) | |
| Insufficient data | 4 | (10.5%) | |
| GBS (as reported) | 7 | (13.7%) | |
| Brighton criteria level 1 | – | – | |
| Brighton criteria level 2 | 6 | (85.7%) | |
| Brighton criteria level 3 | – | – | |
| Misclassification | 1 | (14.3%) | |
| ADEM (as reported) | 6 | (11.8%) | |
| Brighton criteria level 1 | 5 | (83.3%) | |
| Brighton criteria level 2 | 1 | (16.6%) | |
| Brighton criteria level 3 | – | – | |
| Myelitis (as reported)b | 5 | (9.4) | |
| Brighton criteria level 2 | 5 | (100%) | |
| Good outcome (for cases with reported outcomes) (percentage) | 35/51 | (68.6%) | 2 |
| Meningoencephalitis | 29/38 | (76.3%) | 2 |
| ADEM | 2/6 | (33.3%) | |
| GBS | 2/7 | (28.6%) | |
| Myelitisb | 2/5 | (40%) | |
| Age in good outcome group (median, IQR (years)) | 32.5 | (18–55) | |
| Age in poor outcome group (median, IQR (years)) | 53 | (21–59) | |
| Therapy (percentage) | 14/53 | (26.4%) | |
| Patient characteristics . | Totals . | . | Missinga . |
|---|---|---|---|
| Gender ratio (M:F) | 45:8 | – | |
| Age (median, range); (years) | 38.5 | (0.1–78) | 1 |
| Medical history | 37 | 16 | |
| Healthy | 31 | (83.8%) | |
| Cardiovascular history | 4 | (10.8%) | |
| Other (end stage renal disease, alcoholic liver disease and undiagnosed HIV) | 2 | (5.4%) | |
| Time from vaccination to symptom onset (median, range);(days) | 15.5 | (2–50) | 1 |
| MRI/CT abnormalities (percentage) | 16/22 | (72.7%) | 31 |
| EEG abnormalities (percentage) | 8/9 | (88.9%) | 44 |
| Lumbar puncture (percentage) | 50/53 | (94.3%) | |
| CSF findings | |||
| WBC > 5/μl | 28/38 | (73.7%) | 15 |
| Protein > 50 mg/dl | 29/38 | (76.3%) | 15 |
| YFV RT-PCR in CSF | 2/9 | (22.2%) | 44 |
| Anti-YFV IgM in CSF | 26/31 | (81.2%) | 22 |
| Meningoencephalitis (as reported) | 38 | (73.1%) | |
| Brighton criteria level 1 | – | – | |
| Brighton criteria level 2 | 25 | (65.8%) | |
| Brighton criteria level 3 | 8 | (21.1%) | |
| Misclassification | 1 | (21.1%) | |
| Insufficient data | 4 | (10.5%) | |
| GBS (as reported) | 7 | (13.7%) | |
| Brighton criteria level 1 | – | – | |
| Brighton criteria level 2 | 6 | (85.7%) | |
| Brighton criteria level 3 | – | – | |
| Misclassification | 1 | (14.3%) | |
| ADEM (as reported) | 6 | (11.8%) | |
| Brighton criteria level 1 | 5 | (83.3%) | |
| Brighton criteria level 2 | 1 | (16.6%) | |
| Brighton criteria level 3 | – | – | |
| Myelitis (as reported)b | 5 | (9.4) | |
| Brighton criteria level 2 | 5 | (100%) | |
| Good outcome (for cases with reported outcomes) (percentage) | 35/51 | (68.6%) | 2 |
| Meningoencephalitis | 29/38 | (76.3%) | 2 |
| ADEM | 2/6 | (33.3%) | |
| GBS | 2/7 | (28.6%) | |
| Myelitisb | 2/5 | (40%) | |
| Age in good outcome group (median, IQR (years)) | 32.5 | (18–55) | |
| Age in poor outcome group (median, IQR (years)) | 53 | (21–59) | |
| Therapy (percentage) | 14/53 | (26.4%) | |
Summary of most important findings of case reports founded in literature.
aMissing refers to the number of cases where the variable was not reported. M, male; F, female; RT-PCR, reverse transcriptase polymerase chain reaction.
bMyelitis was diagnosed in five cases (9.4%), three of whom had concurrent meningoencephalitis.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
